Gerald H. Sokol - Sep 16, 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC. (TYME)

Role
Director
Signature
By: /s/ Richard Cunningham as attorney-in-fact for Gerald H. Sokol
Stock symbol
TYME
Transactions as of
Sep 16, 2022
Transactions value $
$0
Form type
4
Date filed
9/16/2022, 06:01 PM
Previous filing
Aug 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYME Common Stock Disposed to Issuer -5.87K -100% 0 Sep 16, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -25K -100% 0 Sep 16, 2022 Common Stock 25K $8.75 Direct F2
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -75K -100% 0 Sep 16, 2022 Common Stock 75K $2.90 Direct F3
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -50K -100% 0 Sep 16, 2022 Common Stock 50K $2.33 Direct F4
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -50K -100% 0 Sep 16, 2022 Common Stock 50K $1.18 Direct F5
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -65K -100% 0 Sep 16, 2022 Common Stock 65K $1.22 Direct F6
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -88K -100% 0 Sep 16, 2022 Common Stock 88K $1.10 Direct F7
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -88K -100% 0 Sep 16, 2022 Common Stock 88K $0.31 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Gerald H. Sokol is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 257 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
F2 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 1,094 shares of Syros common stock for $199.68 per share, after giving effect to the Reverse Split.
F3 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,286 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.
F4 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split.
F5 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.
F6 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.
F7 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.
F8 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.